

Microwave Assisted Synthesis, Characterization and Evaluation for Antimicrobial Activity of Novel 1, 5-Benzothiazepines

ABSTRACT:

Aims: 1,5-benzothiazepine ring is privileged aromatic heterocycles of interest to organic and medicinal chemists because of its ease of synthesis and biological activities. This study aims to synthesize new series of 1, 5-benzothiazepine by direct and efficient microwave assistance and to evaluate for antimicrobial activity by MIC method.

Place and Duration of Study: The study was conducted at Department of Pharmaceutical Chemistry, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Guntur-19, A. P. from January, 2019 to October, 2021.

Methodology: 1, 5-benzothiazepines (**BT-21 to BT-40**) were synthesized by microwave irradiation. The structures of the products were established by elemental analysis, FTIR, $^1\text{H-NMR}$, $^{13}\text{C-NMR}$ and mass spectroscopic studies. The synthesized compounds were also evaluated for their Antimicrobial activity by MIC method.

Results: The microwave assisted synthetic procedure adopted yielded the 1,5-benzothiazepine derivatives **BT-21 to BT-40** in good amounts and at a lesser time span. The synthesized 1, 5-benzothiazepine derivatives showed good to moderate antibacterial and antifungal activities. **BT-25** having a dihydroxy-methyl-phenyl moiety proved to be more potent against all selected bacterial strains, *B.subtilis*, *S.aureus*, *E.coli* and *P.aeruginosa* with a MIC value of 64 $\mu\text{g/mL}$. **BT-33** having fluorophenyl moiety, **BT-35** having hydroxyl-nitrophenyl moiety and **BT-40** having dibromophenyl moiety proved to be more potent against all selected fungal strains, *A.niger* and *C.tropicalis* with a MIC value of 16 $\mu\text{g/mL}$.

Conclusion: These results showed that the synthesized 1, 5-benzothiazepine derivatives have better scope for further development as antimicrobial agents.

Keywords: 1, 5-benzothiazepines; $^1\text{H-NMR}$; antibacterial; antifungal.

1. INTRODUCTION

The design and synthesis of heterocyclic hybrids have received greater attention due to their ease of synthesis and improved biological properties [1]. The structures that evolve from such conjugation are usually rigid frameworks that can show the appended rings in a well-defined fashion that is necessary for molecular recognition of the biological target. Usually, the variable nature of these functionalities defines the selectivity on a privileged core for a particular target. 1, 5-Benzothiazepines (**1** and **2**) are seven-membered heterocyclic compounds containing nitrogen and sulphur as hetero atoms with diverse bioactivities [2-6]. 1,5-Benzothiazepines are the most well-known representatives of benzologs of 1,4-thiazepine (**3**) and one of the three possible benzo-condensed derivatives, viz. 1,4-(**4**), 4,1- (**5**) and 1,5-benzothiazepines [6-10]. 1,5-benzothiazepine ring is privileged aromatic heterocycles of interest to organic and medicinal chemists because of its ease of synthesis and biological activities.




Image 1. 1, 5-Benzothiazepine scaffold is prominent in a variety of drugs used in the treatment of different complications.

1, 5-Benzothiazepine scaffold is prominent in a variety of drugs used in the treatment of different complications. The first molecule of 1,5-benzothiazepine used clinically was Diltiazem, followed by Clentiazem, for their cardiovascular action. Some of the 1,5- benzothiazepine derivatives were also used clinically for CNS disorders which includes Thiazesim and Quetiapine fumarate. Moreover, 1,5-benzothiazepine moiety is a privileged class of pharmacophore, as compounds bearing this structural unit possess a broad spectrum of biological activities such as anticonvulsant, Ca²⁺ channel antagonist, antianginal, anti HIV, squalene synthetase inhibitor, V2 arginine vasopressin receptor antagonist, and HIV-1 reverse transcriptase inhibitor [11-19]. Therefore, the 1, 5-benzothiazepines are useful compounds in the drug research which has stimulated the invention of a wide range of synthetic methods for their preparation and chemical transformations [20-34]. In the present study, new series of 1,5-benzothiazepine derivatives has been synthesized by a direct and efficient microwave assistance and evaluated for antimicrobial activity by MIC method.

2. MATERIAL AND METHODS

All the reactions were carried out under specified laboratory conditions. All the synthetic work was done by procuring laboratory grade reagents and analytical grade solvents. Pre-coated silica gel 60 F₂₅₄ plates were used for thin-layer chromatography (TLC) and the spots on the TLC plates were visualized by UV lamp (254 nm). The products were purified by recrystallization using suitable solvents. Melting points were determined by Digital melting point apparatus and were uncorrected. FT-IR spectra were recorded on Bruker Vertex 80v spectrometer using potassium bromide discs and the absorption band values are given in cm⁻¹. ¹H NMR and ¹³C NMR spectra were recorded on Bruker AMX 400 NMR spectrophotometer using Tetramethyl silane (TMS) as internal standard and the chemical shift values are given in parts per million (ppm) relative to TMS. Mass spectra (MS) were recorded on Agilent 6100 QQQ ESI mass spectrophotometer by electron spray ionization technique.

2.1. General Procedure for Synthesis of 1, 3-substituted-prop-2-ene-1-ones [C-21 to C-40]

In this method, acetylated α -naphthol (0.01 mol), aromatic aldehyde (0.011mol) were taken in 5ml of ethanol and poured in 100ml Erlenmeyer borosil flask. To this reaction mixture, 4ml basic alumina was added. The reaction mixture was thoroughly mixed and irradiated inside a microwave for 2-3 minutes at medium level 600W. After completion of reaction, mixture was cooled and the product was extracted with ethanol. (Figure 1)




Figure 1: Scheme for the synthesis of 1, 3-substituted-prop-2-ene-1-ones [C-21 to C-40]

2.2. General Procedure for Synthesis of 2,3-dihydro-2-substituted-4(naphthalene-2-ol)-yl--1,5-benzothiazepines (BT-21 to BT-40)

A mixture of (0.01 mol) 1,3-substituted- prop-2-en-1-one and (0.01 mol, 1.25ml) 2-aminothiophenol and pinch of potassium acetate as catalyst were thoroughly mixed and taken in a clean borosil beaker. The solvent- free reaction mixture was then subjected to microwave irradiation for 2-3 minutes at 80-85°C. The reaction mixture was then allowed to cool to room temperature and then poured cold water in the mixture and stirred vigorously. Products were washed with water to remove the catalyst, filtered, dried and recrystallized by ethanol. (Figure 2)




Figure 2: Scheme for the synthesis of 2, 3-dihydro-2-substituted-4(naphthalene-2-ol)-yl-1, 5-benzothiazepines (BT-21 to BT-40)

2.3. Antimicrobial activity:

The antimicrobial (antibacterial and antifungal) activities of the novel benzothiazepines was evaluated against selected bacterial and fungal strains using standard experimental procedures as described in the literature [35]. The standard strains were procured from the American Type Culture Collection (ATCC) and Gene Bank, Institute of Microbial Technology, Chandigarh, India. The bacterial strains selected for the study were *Bacillus subtilis* (ATCC-60511), *Staphylococcus aureus* (ATCC-11632), *Escherichia coli* (ATCC-10536), and *Pseudomonas aeruginosa* (ATCC-10145) whereas the fungal strains include *Aspergillus niger* (ATCC-6275) and *Candida tropicalis* (ATCC-1369). Ampicillin was used as positive control for antibacterial activity and fluconazole for antifungal activity.

Antibacterial activity was performed using nutrient agar medium whereas Potato Dextrose-Agar medium was used for antifungal testing. 2.048 mg of each test compound was taken in vials separately. Then 2 mL of methanol was added. Thus, a solution with a concentration of 1.024 mg/mL was obtained. All the experiments were carried out in triplicate and the results are presented as the mean of three independent experiments. The microbial strains were grown at 37 °C in their respective nutrient medium and diluted in sterile nutrient broth medium to get a suspension containing 10^7 cells/mL and this suspension was used as the inoculum. All the test tubes were incubated for 18 h at 37 °C. A similar experiment with inoculum, medium and methanol without compound was furthermore performed to confirm that there is no inhibitory effect of methanol used for the dilutions. The test tube number in which the first sign of the growth of the organism observed was noted using a spectrophotometer. The MIC was determined for all the compounds by taking that concentration used in the test tube number just before the test tube number where the first sign of growth observed [36].

3. RESULTS AND DISCUSSION

3.1. Characterization of Synthesized compounds BT-21 to BT-40:

1,5-benzothiazepines (**BT-21 to BT-40**) described here were synthesized following the synthetic routes outlined in Scheme. In the Step-1, to synthesize 1, 3-substituted-prop-2-ene-1-ones (**C-21 to C-40**), α -naphthol was irradiated with substituted aromatic and hetero aromatic aldehydes. Compound **C-21**, analysed for molecular formula $C_{19}H_{13}BrO_2$, m.p. 144-146°C, exhibited $[M^+]$, at m/z 353 and also a satellite peak $[M + 2]$ at m/z 355 with 1:1 intensity in its positive ion mode electron spray ionization mass spectrum.

The I.R (cm^{-1}) spectrum showed the characteristic absorption bands at 3455 (-O-H), 1655 (C=O), 1602 (C=C of Ar) and 795 (C-Br). The ^1H NMR spectrum showed the characteristic signals of CO-CH= and =CH-Ar at δ 6.65 and 7.42 as doublets ($J = 15.58\text{Hz}$) respectively confirming the *trans* geometry at the ethylenic double bond of the molecule. The spectrum also showed peaks in between 7.47-8.2 δ integrated for ten protons must be the aromatic protons. The ^{13}C NMR (δ ppm) spectrum exhibited the characteristic signals at δ 119.3 (1C, s), 119.5 (1C, s), 121.2 (1C, s), 122.2 (1C, s), 122.3 (1C, s), 124.8 (1C, s), 126.4-126.5 (2C, 126.4 (s), 126.4 (s)), 127.1 (1C, s), 127.7 (1C, s), 127.9 (2C, s), 130.3 (1C, s), 131.7 (2C, s), 134.5 (1C, s), 144.1 (1C, s), 162.4 (1C, s), 191.9 (1C, s). The values are consistent with the proposed structure for the compound. The results of elemental analysis were also in close agreement with those of the calculated values. Based on the above spectral data and elemental analysis, the structure of the compound **C-21** was confirmed as (E)-3-(4-bromophenyl)-1-(1-hydroxynaphthalen-2-yl)prop-2-en-1-one. By adopting the above synthetic procedure, compounds **C-22 to C-40** were also synthesized. $[\text{M}^+]$, 351.15, $[\text{M} + 2]$

In the Step-2, to synthesize 2, 3-dihydro-2-substituted-4(naphthalene-2-ol)-yl--1, 5-benzothiazepines (**BT-21 to BT-40**), a mixture of 1, 3-substituted-prop-2-en-1-one and 2-aminothiophenol and pinch of potassium acetate as catalyst were thoroughly mixed and then subjected to microwave irradiation. The compound **BT-21** was analysed for molecular formula $\text{C}_{25}\text{H}_{18}\text{BrNOS}$, m.p. $154-156^\circ\text{C}$, well supported by a $[\text{M}^+]$ at m/z 463 and also a satellite peak $[\text{M} + 2]$ at m/z 465 with 1:1 intensity in its positive mode electron spray ionization mass spectrum. The IR spectrum (cm^{-1}) showed the characteristic bands at 3355 (-O-H), 1505 (C=C of Ar), 790 (C-Br) 1595 (C=N), 1390 (C-N) and 665 (C-S). The ^1H NMR spectrum of compound **BT-21** showed characteristic signals of $\text{C}_2\text{-H}$ protons at δ 5.2 as doublet ($J = 9.76\text{Hz}$), $\text{C}_3\text{-H-3a}$ protons at δ 3.09 as doublet ($J = 15.79\text{Hz}$) and $\text{C}_3\text{-H-3b}$ at δ 3.04 as doublet ($J = 15.79\text{Hz}$). The spectrum also accounted for the other twelve aromatic protons in between δ 6.939 to 8.02. The ^{13}C NMR spectrum of compound **BT-21** accounted for all the carbons whose resonances appeared at the following δ values: 29.2 (1C, s), 46.3 (1C, s), 118.4 (1C, s), 122.3 (1C, s), 122.5 (1C, s), 124.7 (1C, s), 125.3 (1C, s), 126.4-126.5 (2C, 126.4 (s), 126.4 (s)), 126.7 (2C, s), 127.5 (1C, s), 127.7 (1C, s), 128.0 (1C, s), 128.2 (1C, s), 128.5 (1C, s), 129.4 (1C, s), 130.6 (1C, s), 131.7 (2C, s), 133.4 (1C, s), 135.8 (1C, s), 148.9 (1C, s), 160.0 (1C, s), 173.5 (1C, s). The results of elemental analysis were also in agreement with those of the calculated values. Based on the above spectral data and elemental analysis, the structure of the compound **BT-21** was confirmed as 1-((E)-2-(4-bromophenyl)-2, 3-dihydrobenzo[b][1,4]thiazepin-4-yl)naphthalen-2-ol. By adopting the above synthetic procedure of **BT-21**, compounds **BT-22 to BT-40** were also synthesized.

3.1.1. 1-(-2-(4-bromophenyl)-2,3-dihydrobenzo[b][1,4]thiazepin-4-yl)naphthalen-2-ol (BT-21)

FT-IR (KBr): 3355 (-O-H), 1505 (C=C of Ar), 790 (C-Br), 1595 (C=N), 1390 (C-N) and 665 (C-S); ^1H NMR (400 MHz, CDCl_3): δ 2.93-3.11 (2H, 3.01 (dd, $J = 15.8, 9.8\text{ Hz}$), 3.04 (dd, $J = 15.8, 1.6\text{ Hz}$)), 5.20 (1H, dd, $J = 9.8, 1.6\text{ Hz}$), 6.88-7.06 (2H, 6.94 (dd, $J = 8.8, 0.5\text{ Hz}$), 6.99 (ddd, $J = 7.8, 7.6, 1.2\text{ Hz}$)), 7.22-7.68 (9H, 7.29 (ddd, $J = 8.1, 7.6, 1.4\text{ Hz}$), 7.36 (ddd, $J = 8.3, 1.4, 0.5\text{ Hz}$), 7.40 (ddd, $J = 8.1, 1.2, 0.5\text{ Hz}$), 7.47 (ddd, $J = 7.8, 1.4, 0.5\text{ Hz}$), 7.47 (ddd, $J = 8.3, 1.9, 0.5\text{ Hz}$), 7.57 (ddd, $J = 8.6, 7.3, 1.9\text{ Hz}$), 7.61 (dddd, $J = 7.9, 7.3, 1.4, 0.5\text{ Hz}$)), 7.80-8.08 (3H, 7.86 (dtt, $J = 7.9, 1.9, 0.5\text{ Hz}$), 7.98 (dtt, $J = 8.8, 1.9, 0.5\text{ Hz}$), 8.02 (dtt, $J = 8.6, 1.4, 0.5\text{ Hz}$)); ^{13}C NMR (100 MHz, CDCl_3): δ 29.2 (1C, s), 46.3 (1C, s), 118.4 (1C, s), 122.3 (1C, s), 122.5 (1C, s), 124.7 (1C, s), 125.3 (1C, s), 126.4-126.5 (2C, 126.4 (s), 126.4 (s)), 126.7 (2C, s), 127.5 (1C, s), 127.7 (1C, s), 128.0 (1C, s), 128.2 (1C, s), 128.5 (1C, s), 129.4 (1C, s), 130.6 (1C,

s), 131.7 (2C, s), 133.4 (1C, s), 135.8 (1C, s), 148.9 (1C, s), 160.0 (1C, s), 173.5 (1C, s); MS (m/z): [M⁺], 463, [M + 2], 465.

3.1.2. 4-(-2,3-dihydro-4-(2-hydroxynaphthalen-1-yl)benzo[b][1,4]thiazepin-2-yl)benzene-1,2,3-triol (BT-22)

FT-IR (KBr): 3370 (-O-H), 1525 (C=C of Ar), 1580 (C=N) and 680 (C-S); ¹H NMR (400 MHz, CDCl₃): δ 2.77-3.01 (2H, 2.85 (dd, J = 15.7, 9.8 Hz), 2.93 (dd, J = 15.7, 1.6 Hz)), 4.92 (1H, dd, J = 9.8, 1.6 Hz), 6.53 (1H, d, J = 8.6 Hz), 6.88-7.06 (3H, 6.94 (dd, J = 8.8, 0.5 Hz), 6.96 (d, J = 8.6 Hz), 6.99 (ddd, J = 7.8, 7.6, 1.2 Hz)), 7.22-7.68 (5H, 7.29 (ddd, J = 8.1, 7.6, 1.4 Hz), 7.40 (ddd, J = 8.1, 1.2, 0.5 Hz), 7.47 (ddd, J = 7.8, 1.4, 0.5 Hz), 7.57 (ddd, J = 8.6, 7.3, 1.9 Hz), 7.61 (dddd, J = 7.9, 7.3, 1.4, 0.5 Hz)), 7.80-8.08 (3H, 7.86 (dtt, J = 7.9, 1.9, 0.5 Hz), 7.98 (ddt, J = 8.8, 1.9, 0.5 Hz), 8.02 (ddt, J = 8.6, 1.4, 0.5 Hz)).

3.1.3. 1-(-2-(2,3-dichlorophenyl)-2,3-dihydrobenzo[b][1,4]thiazepin-4-yl)naphthalen-2-ol (BT-23)

FT-IR (KBr): 3375 (-O-H), 1515 (C=C of Ar), 590 (C-Cl), 1595 (C=N) and 690 (C-S); ¹H NMR (400 MHz, CDCl₃): δ 2.97-3.24 (2H, 3.05 (dd, J = 15.8, 9.8 Hz), 3.17 (dd, J = 15.8, 1.6 Hz)), 5.27 (1H, dd, J = 9.8, 1.6 Hz), 6.97-7.68 (10H, 7.03 (dd, J = 8.8, 0.5 Hz), 7.15 (ddd, J = 7.8, 7.6, 1.2 Hz), 7.29 (ddd, J = 8.1, 7.6, 1.4 Hz), 7.29 (dd, J = 8.1, 1.1 Hz), 7.37 (dd, J = 8.1, 7.8 Hz), 7.40 (ddd, J = 8.1, 1.2, 0.5 Hz), 7.47 (ddd, J = 7.8, 1.4, 0.5 Hz), 7.54 (dd, J = 7.8, 1.1 Hz), 7.57 (ddd, J = 8.6, 7.3, 1.9 Hz), 7.61 (dddd, J = 7.9, 7.3, 1.4, 0.5 Hz)), 7.80-8.08 (3H, 7.86 (dtt, J = 7.9, 1.9, 0.5 Hz), 7.98 (ddt, J = 8.8, 1.9, 0.5 Hz), 8.02 (ddt, J = 8.6, 1.4, 0.5 Hz)).

3.1.4. 2-(-2,3-dihydro-4-(2-hydroxynaphthalen-1-yl)benzo[b][1,4]thiazepin-2-yl)benzene-1,3,5-triol (BT-24)

FT-IR (KBr): 3340 (-O-H), 1530 (C=C of Ar), 1590 (C=N) and 690 (C-S); ¹H NMR (400 MHz, CDCl₃): δ 2.72-2.90 (2H, 2.79 (dd, J = 15.1, 1.6 Hz), 2.82 (dd, J = 15.1, 9.8 Hz)), 5.01 (1H, dd, J = 9.8, 1.6 Hz), 6.15 (2H, d, J = 2.5 Hz), 6.88-7.06 (2H, 6.94 (dd, J = 8.8, 0.5 Hz), 6.99 (ddd, J = 7.8, 7.6, 1.2 Hz)), 7.22-7.68 (5H, 7.29 (ddd, J = 8.1, 7.6, 1.4 Hz), 7.40 (ddd, J = 8.1, 1.2, 0.5 Hz), 7.47 (ddd, J = 7.8, 1.4, 0.5 Hz), 7.57 (ddd, J = 8.6, 7.3, 1.9 Hz), 7.61 (dddd, J = 7.9, 7.3, 1.4, 0.5 Hz)), 7.80-8.08 (3H, 7.86 (dtt, J = 7.9, 1.9, 0.5 Hz), 7.98 (ddt, J = 8.8, 1.9, 0.5 Hz), 8.02 (ddt, J = 8.6, 1.4, 0.5 Hz)).

3.1.5. 4-(-2,3-dihydro-4-(2-hydroxynaphthalen-1-yl)benzo[b][1,4]thiazepin-2-yl)-5-methylbenzene-1,3-diol (BT-25)

FT-IR (KBr): 3345 (-O-H), 1505 (C=C of Ar), 1595 (C=N) and 679 (C-S); ¹H NMR (400 MHz, CDCl₃): δ 2.38 (3H, s), 2.79-2.95 (2H, 2.87 (dd, J = 15.7, 9.8 Hz), 2.87 (dd, J = 15.7, 1.6 Hz)), 5.10 (1H, dd, J = 9.8, 1.6 Hz), 6.32 (1H, d, J = 2.7 Hz), 6.63 (1H, d, J = 2.7 Hz), 6.97-7.68 (7H, 7.03 (dd, J = 8.8, 0.5 Hz), 7.15 (ddd, J = 7.8, 7.6, 1.2 Hz), 7.29 (ddd, J = 8.1, 7.6, 1.4 Hz), 7.40 (ddd, J = 8.1, 1.2, 0.5 Hz), 7.47 (ddd, J = 7.8, 1.4, 0.5 Hz), 7.57 (ddd, J = 8.6, 7.3, 1.9 Hz), 7.61 (dddd, J = 7.9, 7.3, 1.4, 0.5 Hz)), 7.80-8.08 (3H, 7.86 (dtt, J = 7.9, 1.9, 0.5 Hz), 7.98 (ddt, J = 8.8, 1.9, 0.5 Hz), 8.02 (ddt, J = 8.6, 1.4, 0.5 Hz)).

3.1.6. 4-(-2,3-dihydro-4-(2-hydroxynaphthalen-1-yl)benzo[b][1,4]thiazepin-2-yl)benzene-1,3-diol (BT-26)

FT-IR (KBr): 3355 (-O-H), 1515 (C=C of Ar), 1605 (C=N) and 695 (C-S); ¹H NMR (400 MHz, CDCl₃): δ 2.77-3.00 (2H, 2.85 (dd, J = 15.7, 9.8 Hz), 2.93 (dd, J = 15.7, 1.6 Hz)), 5.05 (1H, dd, J = 9.8, 1.6 Hz), 6.44-6.60 (2H, 6.50 (dd, J = 7.7, 2.8 Hz), 6.55 (dd, J = 2.8, 0.4 Hz)), 6.88-7.06 (2H, 6.94 (dd, J = 8.8, 0.5 Hz), 6.99 (ddd, J = 7.8, 7.6, 1.2 Hz)), 7.16-7.68 (6H, 7.22 (dd, J = 7.7, 0.4 Hz), 7.29 (ddd, J = 8.1, 7.6, 1.4 Hz), 7.40 (ddd, J = 8.1, 1.2, 0.5 Hz), 7.47 (ddd, J = 7.8, 1.4, 0.5 Hz), 7.57 (ddd, J = 8.6, 7.3, 1.9 Hz), 7.61 (dddd, J = 7.9, 7.3, 1.4, 0.5 Hz)), 7.80-8.08 (3H, 7.86 (dtt, J = 7.9, 1.9, 0.5 Hz), 7.98 (ddt, J = 8.8, 1.9, 0.5 Hz), 8.02 (ddt, J = 8.6, 1.4, 0.5 Hz)).

3.1.7. 1-(-2,3-dihydro-2-(2,4,6-trimethoxyphenyl)benzo[b][1,4]thiazepin-4-yl)naphthalen-2-ol (BT-27)

FT-IR (KBr): 3360 (-O-H), 1530 (C=C of Ar), 1594 (C=N) and 690 (C-S); ¹H NMR (400 MHz, CDCl₃): δ 2.70-2.96 (2H, 2.77 (dd, *J* = 14.4, 1.6 Hz), 2.88 (dd, *J* = 14.4, 9.8 Hz)), 3.69-3.82 (9H, 3.74 (s), 3.77 (s)), 4.93 (1H, dd, *J* = 9.8, 1.6 Hz), 6.16 (2H, d, *J* = 2.0 Hz), 6.97-7.68 (7H, 7.03 (dd, *J* = 8.8, 0.5 Hz), 7.15 (ddd, *J* = 7.8, 7.6, 1.2 Hz), 7.29 (ddd, *J* = 8.1, 7.6, 1.4 Hz), 7.40 (ddd, *J* = 8.1, 1.2, 0.5 Hz), 7.47 (ddd, *J* = 7.8, 1.4, 0.5 Hz), 7.57 (ddd, *J* = 8.6, 7.3, 1.9 Hz), 7.61 (dddd, *J* = 7.9, 7.3, 1.4, 0.5 Hz)), 7.80-8.08 (3H, 7.86 (dtt, *J* = 7.9, 1.9, 0.5 Hz), 7.98 (dtt, *J* = 8.8, 1.9, 0.5 Hz), 8.02 (dtt, *J* = 8.6, 1.4, 0.5 Hz)).

3.1.8. 1-(-2,3-dihydro-2-(2,4-dimethoxyphenyl)benzo[b][1,4]thiazepin-4-yl)naphthalen-2-ol (BT-28)

FT-IR (KBr): 3410 (-O-H), 1495 (C=C of Ar), 1590 (C=N) and 685 (C-S); ¹H NMR (400 MHz, CDCl₃): δ 2.72-2.95 (2H, 2.80 (dd, *J* = 15.7, 9.8 Hz), 2.88 (dd, *J* = 15.7, 1.6 Hz)), 3.68-3.81 (6H, 3.73 (s), 3.76 (s)), 5.02 (1H, dd, *J* = 9.8, 1.6 Hz), 6.55-6.75 (2H, 6.60 (dd, *J* = 2.6, 0.5 Hz), 6.68 (dd, *J* = 7.7, 2.6 Hz)), 6.94 (1H, dd, *J* = 8.8, 0.5 Hz), 7.08-7.68 (7H, 7.15 (ddd, *J* = 7.8, 7.6, 1.2 Hz), 7.20 (dd, *J* = 7.7, 0.5 Hz), 7.29 (ddd, *J* = 8.1, 7.6, 1.4 Hz), 7.40 (ddd, *J* = 8.1, 1.2, 0.5 Hz), 7.47 (ddd, *J* = 7.8, 1.4, 0.5 Hz), 7.57 (ddd, *J* = 8.6, 7.3, 1.9 Hz), 7.61 (dddd, *J* = 7.9, 7.3, 1.4, 0.5 Hz)), 7.80-8.08 (3H, 7.86 (dtt, *J* = 7.9, 1.9, 0.5 Hz), 7.98 (dtt, *J* = 8.8, 1.9, 0.5 Hz), 8.02 (dtt, *J* = 8.6, 1.4, 0.5 Hz)).

3.1.9. 2-(2,3-dihydro-4-(2-hydroxynaphthalen-1-yl)benzo[b][1,4]thiazepin-2-yl)benzene-1,4-diol (BT-29)

FT-IR (KBr): 3390 (-O-H), 1505 (C=C of Ar), 1569 (C=N) and 695 (C-S); ¹H NMR (400 MHz, CDCl₃): δ 2.92-3.21 (2H, 3.00 (dd, *J* = 15.8, 9.8 Hz), 3.14 (dd, *J* = 15.8, 1.6 Hz)), 5.13 (1H, dd, *J* = 9.8, 1.6 Hz), 6.39 (1H, dd, *J* = 2.8, 0.5 Hz), 6.68 (1H, dd, *J* = 8.6, 0.5 Hz), 6.81 (1H, dd, *J* = 8.6, 2.8 Hz), 6.88-7.06 (2H, 6.94 (dd, *J* = 8.8, 0.5 Hz), 6.99 (ddd, *J* = 7.8, 7.6, 1.2 Hz)), 7.22-7.68 (5H, 7.29 (ddd, *J* = 8.1, 7.6, 1.4 Hz), 7.40 (ddd, *J* = 8.1, 1.2, 0.5 Hz), 7.47 (ddd, *J* = 7.8, 1.4, 0.5 Hz), 7.57 (ddd, *J* = 8.6, 7.3, 1.9 Hz), 7.61 (dddd, *J* = 7.9, 7.3, 1.4, 0.5 Hz)), 7.80-8.08 (3H, 7.86 (dtt, *J* = 7.9, 1.9, 0.5 Hz), 7.98 (dtt, *J* = 8.8, 1.9, 0.5 Hz), 8.02 (dtt, *J* = 8.6, 1.4, 0.5 Hz)).

3.1.10. 1-(-2,3-dihydro-2-(2,5-dimethoxyphenyl)benzo[b][1,4]thiazepin-4-yl)naphthalen-2-ol (BT-30)

FT-IR (KBr): 3365 (-O-H), 1515 (C=C of Ar), 1585 (C=N) and 690 (C-S); ¹H NMR (400 MHz, CDCl₃): δ 2.95 (1H, dd, *J* = 15.8, 9.8 Hz), 3.17 (1H, dd, *J* = 15.8, 1.6 Hz), 3.72-3.85 (6H, 3.77 (s), 3.80 (s)), 5.10 (1H, dd, *J* = 9.8, 1.6 Hz), 6.50-6.84 (3H, 6.55 (dd, *J* = 2.8, 0.5 Hz), 6.66 (dd, *J* = 8.6, 0.5 Hz), 6.78 (dd, *J* = 8.6, 2.8 Hz)), 6.97-7.68 (7H, 7.03 (dd, *J* = 8.8, 0.5 Hz), 7.15 (ddd, *J* = 7.8, 7.6, 1.2 Hz), 7.29 (ddd, *J* = 8.1, 7.6, 1.4 Hz), 7.40 (ddd, *J* = 8.1, 1.2, 0.5 Hz), 7.47 (ddd, *J* = 7.8, 1.4, 0.5 Hz), 7.57 (ddd, *J* = 8.6, 7.3, 1.9 Hz), 7.61 (dddd, *J* = 7.9, 7.3, 1.4, 0.5 Hz)), 7.80-8.08 (3H, 7.86 (dtt, *J* = 7.9, 1.9, 0.5 Hz), 7.98 (dtt, *J* = 8.8, 1.9, 0.5 Hz), 8.02 (dtt, *J* = 8.6, 1.4, 0.5 Hz)).

3.1.11. 1-(2-(2,6-dichlorophenyl)-2,3-dihydrobenzo[b][1,4]thiazepin-4-yl)naphthalen-2-ol (BT-31)

FT-IR (KBr): 3340 (-O-H), 1505 (C=C of Ar), 610 (C-Cl), 1605 (C=N) and 695 (C-S); ¹H NMR (400 MHz, CDCl₃): δ 3.01-3.29 (2H, 3.10 (dd, *J* = 15.8, 9.8 Hz), 3.22 (dd, *J* = 15.8, 1.6 Hz)), 5.33 (1H, dd, *J* = 9.8, 1.6 Hz), 6.97-7.68 (10H, 7.03 (dd, *J* = 8.8, 0.5 Hz), 7.15 (ddd, *J* = 7.8, 7.6, 1.2 Hz), 7.29 (ddd, *J* = 8.1, 7.6, 1.4 Hz), 7.39 (dd, *J* = 8.1, 1.8 Hz), 7.40 (t, *J* = 8.1 Hz), 7.40 (ddd, *J* = 8.1, 1.2, 0.5 Hz), 7.47 (ddd, *J* = 7.8, 1.4, 0.5 Hz), 7.57 (ddd, *J* = 8.6, 7.3, 1.9 Hz), 7.61 (dddd, *J* = 7.9, 7.3, 1.4, 0.5 Hz)), 7.80-8.08 (3H, 7.86 (dddt, *J* = 7.9, 1.9, 1.6, 0.5 Hz), 7.98 (dtt, *J* = 8.8, 1.6, 0.5 Hz), 8.02 (dtt, *J* = 8.6, 1.4, 0.5 Hz)).

3.1.12. 1-(2-(2-bromophenyl)-2,3-dihydrobenzo[b][1,4]thiazepin-4-yl)naphthalen-2-ol (BT-32)

FT-IR (KBr): 3365 (-O-H), 1520 (C=C of Ar), 805 (C-Br), 1600 (C=N) and 695 (C-S); ¹H NMR (400 MHz, CDCl₃): δ 2.96-3.21 (2H, 3.04 (dd, *J* = 15.8, 9.8 Hz), 3.14 (dd, *J* = 15.8, 1.6 Hz)), 5.25 (1H, dd, *J* = 9.8, 1.6 Hz), 6.91-7.68 (11H, 6.97 (ddd, *J* = 8.0, 1.5, 0.5 Hz), 7.03 (dd, *J* = 8.8, 0.5 Hz), 7.10 (ddd, *J* = 8.0, 7.5, 1.6 Hz), 7.15 (ddd, *J* = 7.8, 7.6, 1.2 Hz), 7.28 (ddd, *J* = 8.0, 7.5, 1.5 Hz), 7.29 (ddd, *J* = 8.1, 7.6, 1.4 Hz), 7.40 (ddd, *J* = 8.1, 1.2, 0.5 Hz), 7.47 (ddd, *J* = 7.8, 1.4, 0.5 Hz), 7.47 (ddd, *J* = 8.0, 1.6, 0.5 Hz), 7.57 (ddd, *J* = 8.6, 7.3, 1.9 Hz), 7.61 (dddd, *J* = 7.9, 7.3, 1.4, 0.5 Hz)), 7.80-8.08 (3H, 7.86 (dtt, *J* = 7.9, 1.9, 0.5 Hz), 7.98 (dtt, *J* = 8.8, 1.9, 0.5 Hz), 8.02 (dtt, *J* = 8.6, 1.4, 0.5 Hz)).

3.1.13. 1-(2-(2-fluorophenyl)-2,3-dihydrobenzo[b][1,4]thiazepin-4-yl)naphthalen-2-ol (BT-33)

FT-IR (KBr): 3350 (-O-H), 1515 (C=C of Ar), 1570 (C=N), 915 (C-F and 695 (C-S)); ¹H NMR (400 MHz, CDCl₃): δ 2.95-3.23 (2H, 3.03 (dd, *J* = 15.8, 9.8 Hz), 3.16 (dd, *J* = 15.8, 1.6 Hz)), 5.20 (1H, dd, *J* = 9.8, 1.6 Hz), 6.88-7.68 (11H, 6.94 (dd, *J* = 8.8, 0.5 Hz), 6.99 (ddd, *J* = 7.8, 7.5, 1.2 Hz), 7.07 (ddd, *J* = 8.3, 1.5, 0.5 Hz), 7.11 (ddd, *J* = 8.0, 1.2, 0.5 Hz), 7.17 (ddd, *J* = 8.0, 7.5, 1.5 Hz), 7.29 (ddd, *J* = 8.1, 7.5, 1.4 Hz), 7.38 (ddd, *J* = 8.3, 7.5, 1.2 Hz), 7.40 (ddd, *J* = 8.1, 1.2, 0.5 Hz), 7.47 (ddd, *J* = 7.8, 1.4, 0.5 Hz), 7.57 (ddd, *J* = 8.6, 7.3, 1.9 Hz), 7.61 (dddd, *J* = 7.9, 7.3, 1.4, 0.5 Hz)), 7.80-8.08 (3H, 7.86 (dt, *J* = 7.9, 1.9, 0.5 Hz), 7.98 (ddt, *J* = 8.8, 1.9, 0.5 Hz), 8.02 (ddt, *J* = 8.6, 1.4, 0.5 Hz)).

3.1.14. 1-(2-(2-ethoxyphenyl)-2,3-dihydrobenzo[*b*][1,4]thiazepin-4-yl)naphthalen-2-ol (BT-34)

FT-IR (KBr): 3360 (-O-H), 1525 (C=C of Ar), 1585 (C=N) and 675 (C-S); ¹H NMR (400 MHz, CDCl₃): δ 1.28 (3H, t, *J* = 7.0 Hz), 2.95 (1H, dd, *J* = 15.8, 9.8 Hz), 3.17 (1H, dd, *J* = 15.8, 1.6 Hz), 3.95-4.07 (2H, 4.01 (q, *J* = 7.0 Hz), 4.01 (q, *J* = 7.0 Hz)), 5.20 (1H, dd, *J* = 9.8, 1.6 Hz), 6.84-7.00 (2H, 6.91 (ddd, *J* = 8.0, 7.6, 1.3 Hz), 6.94 (dd, *J* = 8.8, 0.5 Hz)), 7.00-7.68 (9H, 7.07 (ddd, *J* = 8.0, 1.3, 0.6 Hz), 7.09 (ddd, *J* = 8.5, 1.3, 0.6 Hz), 7.15 (ddd, *J* = 7.8, 7.6, 1.2 Hz), 7.24 (ddd, *J* = 8.5, 7.6, 1.3 Hz), 7.29 (ddd, *J* = 8.1, 7.6, 1.4 Hz), 7.40 (ddd, *J* = 8.1, 1.2, 0.5 Hz), 7.47 (ddd, *J* = 7.8, 1.4, 0.5 Hz), 7.57 (ddd, *J* = 8.6, 7.3, 1.9 Hz), 7.61 (dddd, *J* = 7.9, 7.3, 1.4, 0.5 Hz)), 7.80-8.08 (3H, 7.86 (dt, *J* = 7.9, 1.9, 0.5 Hz), 7.98 (ddt, *J* = 8.8, 1.9, 0.5 Hz), 8.02 (ddt, *J* = 8.6, 1.4, 0.5 Hz)).

3.1.15. 1-(2,3-dihydro-2-(2-hydroxy-3-nitrophenyl)benzo[*b*][1,4]thiazepin-4-yl)naphthalen-2-ol (BT-35)

FT-IR (KBr): 3365 (-O-H), 1515 (C=C of Ar), 1570 (C=N) and 690 (C-S); ¹H NMR (400 MHz, CDCl₃): δ 2.99 (1H, dd, *J* = 15.8, 9.8 Hz), 3.19 (1H, dd, *J* = 15.8, 1.6 Hz), 5.35 (1H, dd, *J* = 9.8, 1.6 Hz), 6.88-7.06 (2H, 6.94 (dd, *J* = 8.8, 0.5 Hz), 6.99 (ddd, *J* = 7.8, 7.6, 1.2 Hz)), 7.22-7.79 (7H, 7.29 (ddd, *J* = 8.1, 7.6, 1.4 Hz), 7.40 (ddd, *J* = 8.1, 1.2, 0.5 Hz), 7.42 (dd, *J* = 7.8, 7.5 Hz), 7.47 (ddd, *J* = 7.8, 1.4, 0.5 Hz), 7.57 (ddd, *J* = 8.6, 7.3, 1.9 Hz), 7.61 (dddd, *J* = 7.9, 7.3, 1.4, 0.5 Hz), 7.73 (dd, *J* = 7.5, 1.9 Hz)), 7.80-8.08 (3H, 7.86 (dt, *J* = 7.9, 1.9, 0.5 Hz), 7.98 (ddt, *J* = 8.8, 1.9, 0.5 Hz), 8.02 (ddt, *J* = 8.6, 1.4, 0.5 Hz)), 8.15 (1H, dd, *J* = 7.8, 1.9 Hz).

3.1.16. 1-(2,3-dihydro-2-(2-hydroxy-3-methoxyphenyl)benzo[*b*][1,4]thiazepin-4-yl)naphthalen-2-ol (BT-36)

FT-IR (KBr): 3375 (-O-H), 1511 (C=C of Ar), 1570 (C=N) and 690 (C-S); ¹H NMR (400 MHz, CDCl₃): δ 2.94-3.22 (2H, 3.02 (dd, *J* = 15.8, 9.8 Hz), 3.15 (dd, *J* = 15.8, 1.6 Hz)), 3.79 (3H, s), 5.00 (1H, dd, *J* = 9.8, 1.6 Hz), 6.59-6.82 (2H, 6.66 (dd, *J* = 8.6, 2.6 Hz), 6.76 (dd, *J* = 8.0, 2.6 Hz)), 6.88-7.14 (3H, 6.94 (dd, *J* = 8.8, 0.5 Hz), 6.99 (ddd, *J* = 7.8, 7.6, 1.2 Hz), 7.07 (dd, *J* = 8.6, 8.0 Hz)), 7.22-7.68 (5H, 7.29 (ddd, *J* = 8.1, 7.6, 1.4 Hz), 7.40 (ddd, *J* = 8.1, 1.2, 0.5 Hz), 7.47 (ddd, *J* = 7.8, 1.4, 0.5 Hz), 7.57 (ddd, *J* = 8.6, 7.3, 1.9 Hz), 7.61 (dddd, *J* = 7.9, 7.3, 1.4, 0.5 Hz)), 7.80-8.08 (3H, 7.86 (dt, *J* = 7.9, 1.9, 0.5 Hz), 7.98 (ddt, *J* = 8.8, 1.9, 0.5 Hz), 8.02 (ddt, *J* = 8.6, 1.4, 0.5 Hz)).

3.1.17. 1-(2,3-dihydro-2-(2-hydroxy-5-methoxyphenyl)benzo[*b*][1,4]thiazepin-4-yl)naphthalen-2-ol (BT-37)

FT-IR (KBr): 3380 (-O-H), 1515 (C=C of Ar), 1575 (C=N) and 685 (C-S); ¹H NMR (400 MHz, CDCl₃): δ 2.94-3.22 (2H, 3.02 (dd, *J* = 15.8, 9.8 Hz), 3.15 (dd, *J* = 15.8, 1.6 Hz)), 3.76 (3H, s), 4.99 (1H, dd, *J* = 9.8, 1.6 Hz), 6.50-6.85 (3H, 6.56 (dd, *J* = 2.8, 0.5 Hz), 6.67 (dd, *J* = 8.6, 0.5 Hz), 6.79 (dd, *J* = 8.6, 2.8 Hz)), 6.88-7.06 (2H, 6.94 (dd, *J* = 8.8, 0.5 Hz), 6.99 (ddd, *J* = 7.8, 7.6, 1.2 Hz)), 7.22-7.68 (5H, 7.29 (ddd, *J* = 8.1, 7.6, 1.4 Hz), 7.40 (ddd, *J* = 8.1, 1.2, 0.5 Hz), 7.47 (ddd, *J* = 7.8, 1.4, 0.5 Hz), 7.57 (ddd, *J* = 8.6, 7.3, 1.9 Hz), 7.61 (dddd, *J* = 7.9, 7.3, 1.4, 0.5 Hz)), 7.80-8.08 (3H, 7.86 (dt, *J* = 7.9, 1.9, 0.5 Hz), 7.98 (ddt, *J* = 8.8, 1.9, 0.5 Hz), 8.02 (ddt, *J* = 8.6, 1.4, 0.5 Hz)).

3.1.18. 1-(2-(3,4-dichlorophenyl)-2,3-dihydrobenzo[*b*][1,4]thiazepin-4-yl)naphthalen-2-ol (BT-38)

FT-IR (KBr): 3355 (-O-H), 1507 (C=C of Ar), 580 (C-Cl), 1590 (C=N) and 690 (C-S); ¹H NMR (400 MHz, CDCl₃): δ 2.93-3.22 (2H, 3.02 (dd, *J* = 15.8, 9.8 Hz), 3.15 (dd, *J* = 15.8, 1.6 Hz)), 5.28 (1H, dd, *J* = 9.8, 1.6 Hz), 6.97-7.68 (10H, 7.03 (dd, *J* = 8.8, 0.5 Hz), 7.15 (ddd, *J* = 7.8, 7.6, 1.2 Hz), 7.29 (ddd, *J* = 8.1,

7.6, 1.4 Hz), 7.28 (dd, $J = 8.2, 1.3$ Hz), 7.40 (ddd, $J = 8.1, 1.2, 0.5$ Hz), 7.46 (dd, $J = 8.2, 0.5$ Hz), 7.47 (ddd, $J = 7.8, 1.4, 0.5$ Hz), 7.47 (dd, $J = 1.3, 0.5$ Hz), 7.57 (ddd, $J = 8.6, 7.3, 1.9$ Hz), 7.61 (dddd, $J = 7.9, 7.3, 1.4, 0.5$ Hz)), 7.80-8.08 (3H, 7.86 (dtt, $J = 7.9, 1.9, 0.5$ Hz), 7.98 (dtt, $J = 8.8, 1.9, 0.5$ Hz), 8.02 (dtt, $J = 8.6, 1.4, 0.5$ Hz)).

3.1.19. 4-(2,3-dihydro-4-(2-hydroxynaphthalen-1-yl)benzo[b][1,4]thiazepin-2-yl)benzene-1,2-diol (BT-39)



FT-IR (KBr): 3350 (-O-H), 1520 (C=C of Ar), 1575 (C=N) and 680 (C-S); ^1H NMR (400 MHz, CDCl_3): δ 2.86-3.14 (2H, 2.94 (dd, $J = 15.8, 9.8$ Hz), 3.07 (dd, $J = 15.8, 1.6$ Hz)), 5.09 (1H, dd, $J = 9.8, 1.6$ Hz), 6.66-6.79 (2H, 6.72 (dd, $J = 8.5, 2.6$ Hz), 6.73 (dd, $J = 8.5, 0.5$ Hz)), 6.88-7.06 (3H, 6.94 (dd, $J = 8.8, 0.5$ Hz), 6.95 (dd, $J = 2.6, 0.5$ Hz), 6.99 (ddd, $J = 7.8, 7.6, 1.2$ Hz)), 7.22-7.68 (5H, 7.29 (ddd, $J = 8.1, 7.6, 1.4$ Hz), 7.40 (ddd, $J = 8.1, 1.2, 0.5$ Hz), 7.47 (ddd, $J = 7.8, 1.4, 0.5$ Hz), 7.57 (ddd, $J = 8.6, 7.3, 1.9$ Hz), 7.61 (dddd, $J = 7.9, 7.3, 1.4, 0.5$ Hz)), 7.80-8.08 (3H, 7.86 (dtt, $J = 7.9, 1.9, 0.5$ Hz), 7.98 (dtt, $J = 8.8, 1.9, 0.5$ Hz), 8.02 (dtt, $J = 8.6, 1.4, 0.5$ Hz)).









3.1.20. 1-(2-(3,4-dibromophenyl)-2,3-dihydrobenzo[b][1,4]thiazepin-4-yl)naphthalen-2-ol (BT-40)









FT-IR (KBr): 3360 (-O-H), 1515 (C=C of Ar), 810 (C-Br) 1585 (C=N) and 670 (C-S); ^1H NMR (400 MHz, CDCl_3): δ 2.94-3.22 (2H, 3.02 (dd, $J = 15.8, 9.8$ Hz), 3.15 (dd, $J = 15.8, 1.6$ Hz)), 5.23 (1H, dd, $J = 9.8, 1.6$ Hz), 6.97-7.68 (10H, 7.03 (dd, $J = 8.8, 0.5$ Hz), 7.15 (ddd, $J = 7.8, 7.6, 1.2$ Hz), 7.20 (dd, $J = 8.1, 1.5$ Hz), 7.29 (ddd, $J = 8.1, 7.6, 1.4$ Hz), 7.40 (ddd, $J = 8.1, 1.2, 0.5$ Hz), 7.41 (dd, $J = 1.5, 0.5$ Hz), 7.47 (ddd, $J = 7.8, 1.4, 0.5$ Hz), 7.49 (dd, $J = 8.1, 0.5$ Hz), 7.57 (ddd, $J = 8.6, 7.3, 1.9$ Hz), 7.61 (dddd, $J = 7.9, 7.3, 1.4, 0.5$ Hz)), 7.80-8.08 (3H, 7.86 (dtt, $J = 7.9, 1.9, 0.5$ Hz), 7.98 (dtt, $J = 8.8, 1.9, 0.5$ Hz), 8.02 (dtt, $J = 8.6, 1.4, 0.5$ Hz)).

Physical characterization and Elemental Analysis data of 1, 5-benzothiazepines were represented in **Table1** and **Table 2**.

Table 1: Physical characterization data of 2,3-dihydro-2-substituted-4(naphthalene-2-ol)-yl--1,5-benzothiazepines (BT-21 to BT-40):

Compound	R	Molecular Formula	Relative Molecular Mass (RMM)	Melting Point ($^{\circ}\text{C}$)	Yield %	Rf value
BT-21		$\text{C}_{25}\text{H}_{18}\text{BrNOS}$	460.39	152-154	76	0.6
BT-22		$\text{C}_{25}\text{H}_{19}\text{NO}_4\text{S}$	420.49	160-162	78	0.4
BT-23		$\text{C}_{25}\text{H}_{17}\text{Cl}_2\text{NOS}$	450.38	138-140	82	0.7

BT-24		$C_{25}H_{19}NO_4S$	420.49	168-170	80	0.5
BT-25		$C_{26}H_{21}NO_3S$	427.51	166-168	75	0.6
BT-26		$C_{25}H_{19}NO_3S$	413.19	160-162	83	0.7
BT-27		$C_{27}H_{24}N_2OS$	471.57	172-174	72	0.8
BT-28		$C_{27}H_{23}NO_3S$	441.53	154-156	82	0.6
BT-29		$C_{25}H_{19}NO_3S$	413.19	158-160	77	0.5
BT-30		$C_{27}H_{23}NO_3S$	441.53	170-172	81	0.8
BT-31		$C_{25}H_{17}Cl_2NOS$	450.38	166-168	79	0.5

BT-32		$C_{25}H_{18}BrNOS$	460.39	180-182	84	0.5
BT-33		$C_{25}H_{18}FNOS$	399.48	174-176	81	0.6
BT-34		$C_{27}H_{23}NO_2S$	425.54	164-166	82	0.6
BT-35		$C_{25}H_{18}N_2O_4S$	442.59	170-172	78	0.8
BT-36		$C_{26}H_{21}NO_3S$	427.51	178-180	80	0.6
BT-37		$C_{26}H_{21}NO_3S$	427.51	166-168	84	0.5
BT-38		$C_{25}H_{17}Cl_2NOS$	450.38	160-162	79	0.6
BT-39		$C_{25}H_{19}NO_3S$	413.19	172-174	86	0.7


BT-40		$C_{25}H_{17}Br_2NOS$	539.28	180-182	74	0.8
-------	---	-----------------------	--------	---------	----	-----

Table 2: Elemental Analysis data of 2, 3-dihydro-2-substituted-4(naphthalene-2-ol)-yl--1,5-benzothiazepines (BT-21 to BT-40):

Compound	% Calculated			%Found		
	C	H	N	C	H	N
BT-21	65.22	3.94	3.04	65.20	3.96	3.06
BT-22	69.91	4.46	3.26	69.82	4.52	3.34
BT-23	66.67	3.8	3.11	66.76	3.72	66.67
BT-24	69.91	4.46	3.26	66.83	4.51	66.85
BT-25	73.04	4.95	3.8	73.12	4.91	3.79
BT-26	72.62	4.63	3.39	72.71	4.67	3.34
BT-27	71.32	5.34	2.97	71.36	5.37	2.89
BT-28	73.44	5.25	3.17	73.51	5.32	3.15
BT-29	72.62	4.63	3.39	72.66	3.41	3.44
BT-30	73.44	5.25	3.17	73.51	5.22	3.19
BT-31	66.67	3.8	3.11	66.72	3.91	3.16
BT-32	65.22	3.94	3.04	65.26	3.89	3.09
BT-33	75.16	4.54	3.51	75.21	4.59	3.46

BT-34	76.21	5.45	3.29	76.24	5.49	3.33
BT-35	67.86	4.1	6.33	67.86	4.09	6.31
BT-36	73.04	4.95	3.8	73.11	4.91	3.77
BT-37	73.04	4.95	3.8	73.12	4.91	3.81
BT-38	66.67	3.8	3.11	66.64	3.82	3.09
BT-39	72.62	4.63	3.39	72.58	4.61	3.40
BT-40	55.68	3.18	2.6	55.64	2.58	2.58

3.2. Antibacterial activity:

The antibacterial activity of the novel benzothiazepines was evaluated against selected bacterial strains using Ampicillin as positive control by MIC method. From the results (**Table 3 & Figure 3**), it is evident that most of the 1,5-benzothiazepines synthesized showed antibacterial activity with different MIC values against the tested organisms, but not comparable with that of the standard. Among the compounds tested, **BT-25** having a dihydroxy-methyl-phenyl moiety proved to be more potent against all selected bacterial strains *B.subtilis*, *S.aureus*, *E.coli* and *P.aeruginosa* with a MIC value of 64 µg/mL. **BT-40** having dibromophenyl moiety proved to be more potent against three selected bacterial strains *S.aureus*, *E.coli* and *P.aeruginosa* with a MIC value of 64 µg/mL.

Table 3: Antibacterial activity of Benzothiazepines (BT-21to BT-40): (Expressed as MIC in µg/mL)

Compound	<i>B.subtilis</i>	<i>S.aureus</i>	<i>E.coli</i>	<i>P.vulgaris</i>
BT-21	256	128	256	128
BT-22	64	128	128	128
BT-23	64	128	64	128
BT-24	128	64	128	64
BT-25	64	64	64	64
BT-26	64	128	64	128
BT-27	128	64	128	128
BT-28	256	128	128	256

BT-29	64	128	128	64
BT-30	128	128	128	128
BT-31	64	128	64	128
BT-32	128	64	64	128
BT-33	256	64	128	256
BT-34	128	128	128	128
BT-35	64	128	64	128
BT-36	128	256	256	128
BT-37	256	256	512	256
BT-38	64	128	64	128
BT-39	64	128	128	64
BT-40	128	64	64	64
Standard (Ampicillin)	< 1	< 1	< 1	< 1




Figure 3: Antibacterial activity of Benzothiazepines (BT-21to BT-40): (Expressed as MIC in µg/mL)

3.3. Antifungal activity:

The antifungal activity of the novel benzothiazepines was evaluated against selected fungal strains using Fluconazole as positive control by MIC method. From the results (**Table 4 & Figure 4**), it is evident that most of the 1, 5-benzothiazepines synthesized showed antifungal activity with different MIC values against the tested organisms, but not comparable with that of the standard. Among the compounds tested, BT-33 having fluorophenyl moiety, BT-35 having hydroxyl-nitrophenyl moiety and BT-40 having dibromophenyl moiety proved to be more potent against all selected fungal strains, *A.niger* and *C.tropicalis* with a MIC value of 16 µg/mL. BT-25 having dihydroxy-methylphenyl moiety and BT-26

having dihydroxyphenyl moiety proved to be more potent against all selected fungal strains, *A.niger* and *C.tropicalis* with a MIC value of 32 µg/mL.

Table 4: Antifungal activity of Benzothiazepines (BT-21to BT-40): (Expressed as MIC in µg/mL)

Compound	<i>Aspergillusniger</i>	<i>Candida tropicalis</i>
BT-21	16	32
BT-22	32	64
BT-23	32	34
BT-24	32	64
BT-25	32	32
BT-26	32	32
BT-27	64	32
BT-28	32	64
BT-29	32	64
BT-30	64	32
BT-31	32	64
BT-32	16	32
BT-33	16	16
BT-34	64	128
BT-35	16	16
BT-36	32	64
BT-37	32	64
BT-38	16	32
BT-39	32	32
BT-40	16	16
Standard (Fluconazole)	< 2	< 2




Figure 4: Antifungal activity of Benzothiazepines (BT-21to BT-40) : (Expressed as MIC in µg/mL)

CONCLUSION:

The microwave assisted synthetic procedure adopted was afforded the 1, 5-benzothiazepine derivatives **BT-21 to BT-40** in good yield at the cost of shorter reaction time. The synthesized 1, 5-benzothiazepine derivatives showed good to moderate antibacterial and antifungal activities. Out of the synthesized compounds, molecules bearing electron releasing group showed good antibacterial activity and molecules bearing electron withdrawing groups showed good antifungal activity. The compounds **BT-25, BT-33 and BT-35** are the promising molecules with antimicrobial properties and have better scope for further development as antimicrobial agents and potency of these compounds is required to be confirmed further by in-vivo screening.

REFERENCES:

1. Gomtsyan A. Heterocycles in drugs and drug discovery. Chemistry of heterocyclic compounds. 2012 Apr 1;48(1):7-10.
2. Anshu, D., Ruby, S., Dharmendra, S., Ashok, L., Asha, S. *Phosphorus, Sulfur, Silicon Relat. Elem.* 2472 (2010);185.
3. Ghotekar DS, Joshi RS, Mandhane PG, Bhagat SS, Gill CH. Synthesis of some biologically important fluorinated 3-chlorochromones and 1, 5-benzothiazepines as antimicrobial and antifungal agents.
4. Desai KG, Desai KR. Microwave enhanced heterocyclization: A convenient procedure for antimicrobial 1, 5-benzothiazepine compounds. *Indian J. Chem.* 2007.
5. Garg N, Chandra T, Jain AB, Kumar A. Synthesis and evaluation of some new substituted benzothiazepine and benzoxazepine derivatives as anticonvulsant agents. *European journal of medicinal chemistry.* 2010 Apr 1;45(4):1529-35.

6. Yamada SI, Mori Y, Morimatsu K, Ishizu Y, Ozaki Y, Yoshioka R, Nakatani T, Seko H. Asymmetric Reduction of a 1, 5-Benzothiazepine Derivative with Sodium Borohydride-(S)- α -Amino Acids: An Efficient Synthesis of a Key Intermediate of Diltiazem. *The Journal of Organic Chemistry*. 1996 Nov 29;61(24):8586-90.
7. Khatib S, Nerya O, Musa R, Shmuel M, Tamir S, Vaya J. Chalcones as potent tyrosinase inhibitors: the importance of a 2, 4-substituted resorcinol moiety. *Bioorganic & medicinal chemistry*. 2005 Jan 17;13(2):433-41.
8. Nowakowska Z. A review of anti-infective and anti-inflammatory chalcones. *European journal of medicinal chemistry*. 2007 Feb 1;42(2):125-37.
9. Go ML, Wu X, Liu XL. Chalcones: an update on cytotoxic and chemoprotective properties. *Current medicinal chemistry*. 2005 Feb 1;12(4):483-99.
10. Cushman M, Nagarathnam D. Cytotoxicities of some flavonoid analogues. *Journal of natural products*. 1991 Nov;54(6):1656-60.
11. Claisen L, Claparède A. Condensationen von ketonen mit aldehyden. *Berichte der deutschen chemischen Gesellschaft*. 1881 Jul;14(2):2460-8.
12. Datta SC, Murti VV, Seshadri TR. Synthesis of 2'-methoxyflavanones. *Indian Journal Of Chemistry*. 1971 Jan 1;9(6):614.
13. Makrandi JK, Kumar S. An efficient synthesis of 2'-Hydroxychalcones. *Asian Journal of Chemistry*. 2004 Apr 1;16(2):1189.
14. Reichel L, Müller K. Eine direkte Synthese des Flavanons. *Chemie und Biochemie der Pflanzenstoffe*, V. Mitteilung*. *Berichte der deutschen chemischen Gesellschaft (A and B Series)*. 1941 Nov 5;74(11):1741-2.
15. Saravanamurugan S, Palanichamy M, Arabindoo B, Murugesan V. Solvent free synthesis of chalcone and flavanone over zinc oxide supported metal oxide catalysts. *Catalysis Communications*. 2005 Jun 1;6(6):399-403.
16. Anjaneyulu AS, Sudha Rani G, Mallavadhani UV, Murthy YL. Synthesis and characterization of some new chalcones and flavanones. *Indian J Heterocycl Chem*. 1994;4(1):9-14.
17. Deshpande AM, Argade NP, Natu AA, Eckman J. Synthesis and screening of a combinatorial library of naphthalene substituted chalcones: inhibitors of leukotriene B₄. *Bioorganic & medicinal chemistry*. 1999 Jun 1;7(6):1237-40.
18. Batterham TJ, Highet RJ. Nuclear magnetic resonance spectra of flavonoids. *Australian Journal of Chemistry*. 1964;17(4):428-39.
19. Hergert HL, Kurth EF. The Infrared Spectra of Lignin and Related Compounds. I. Characteristic Carbonyl and Hydroxyl Frequencies of Some Flavanones, Flavones, Chalcones and Acetophenones. *Journal of the American Chemical Society*. 1953 Apr;75(7):1622-5.
20. Urbanski MJ, Chen RH, Demarest KT, Gunnet J, Look R, Ericson E, Murray WV, Rybczynski PJ, Zhang X. 2, 5-Disubstituted 3, 4-dihydro-2H-benzo [b][1, 4] thiazepines as potent and selective V₂ arginine vasopressin receptor antagonists. *Bioorganic & medicinal chemistry letters*. 2003 Nov 17;13(22):4031-4.

21. Hekmatshoar R, Sadjadi S, Shiri S, Heravi MM, Beheshtiha YS. Green protocol for synthesis of 1, 5-benzodiazepines and 1, 5-benzothiazepines in the presence of nanocrystalline aluminum oxide. *Synthetic Communications®*. 2009 Jun 23;39(14):2549-59.
22. Pan XQ, Zou JP, Huang ZH, Zhang W. Ga (OTf) 3-promoted condensation reactions for 1, 5-benzodiazepines and 1, 5-benzothiazepines. *Tetrahedron Letters*. 2008 Sep 1;49(36):5302-8.
23. Sharma G, Kumar R, Chakraborti AK. Fluoroboric acid adsorbed on silica-gel (HBF₄-SiO₂) as a new, highly efficient and reusable heterogeneous catalyst for thia-Michael addition to α , β -unsaturated carbonyl compounds. *Tetrahedron Letters*. 2008 Jun 30;49(27):4272-5.
24. Sharma G, Kumar R, Chakraborti AK. 'On water' synthesis of 2, 4-diaryl-2, 3-dihydro-1, 5-benzothiazepines catalysed by sodium dodecyl sulfate (SDS). *Tetrahedron Letters*. 2008 Jun 30;49(27):4269-71.
25. GL K. Kumar R. Chakraborti AK. *Synthesis*. 2007;541
26. Khatik GL, Sharma G, Kumar R, Chakraborti AK. Scope and limitations of HClO₄-SiO₂ as an extremely efficient, inexpensive, and reusable catalyst for chemoselective carbon-sulfur bond formation. *Tetrahedron*. 2007 Jan 29;63(5):1200-10.
27. Orlov VD, Kolos NN, Ruzhitskaya NN. 2, 4-Diaryl-2, 3-dihydrobenzo [b][1, 4] thiazepines. *Chemistry of Heterocyclic Compounds*. 1983 Dec 1;19(12):1293-7.
28. Yang C, Fang L, Wu L, Yan F. Synthesis of 2-aryl-2, 3-dihydroquinolin-4 (1H)-ones using wet cyanuric chloride under solvent-free conditions. *Asian Journal of Chemistry*. 2010 Sep 15;22(8):6031.
29. Sharma GV, Reddy JJ, Lakshmi PS, Krishna PR. A versatile and practical synthesis of bis (indolyl) methanes/bis (indolyl) glycoconjugates catalyzed by trichloro-1, 3, 5-triazine. *Tetrahedron Letters*. 2004 Oct 4;45(41):7729-32.
30. Bigdeli MA, Heravi MM, Mahdavinia GH. Wet cyanuric chloride catalyzed simple and efficient synthesis of 14-aryl or alkyl-14-H-dibenzo [a, j] xanthenes. *Catalysis Communications*. 2007 Nov 1;8(11):1595-8.
31. Kotalwar SS, Kale AD, Kohire RB, Jagrut VB. Microwave assisted synthesis of 1, 5-benzothiazepines using greener reaction medium. *Asian Journal of Chemistry*. 2019 Mar 28;31(5):993-6.
32. Sternbach LH. The benzodiazepine story. *Progress in Drug Research*. 1978:229-66.
33. Xu J, Jin S. Thermal cycloaddition reaction of symmetrical and unsymmetrical α -diazo- β -diketones with 4-aryl-2-methyl-2, 3-dihydro-1, 5-benzothia/diazepines. *Heteroatom Chemistry: An International Journal of Main Group Elements*. 1999;10(1):35-40.
34. Prasad C, Rao AV, Rao MV. 1, 5-benzothiazepines: an update. *ChemInform*. 2014 Dec 29;45(52):no-.
35. Andrews JM. Determination of minimum inhibitory concentrations. *Journal of antimicrobial Chemotherapy*. 2001 Jul 1;48(suppl-1):5-16.
36. Kasetti Ashok BA, Singhvi I, Ravindra N, Shaik AB. Antimicrobial and antitubercular evaluation of some new 5-amino-1, 3, 4-thiadiazole-2-thiol derived Schiff bases. *Rev. Roum. Chim*. 2020;65(9):771-6.

UNDER PEER REVIEW